DF Dent & Co. Inc. maintained its stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, Holdings Channel reports. The fund owned 8,353 shares of the company’s stock at the end of the first quarter. DF Dent & Co. Inc.’s holdings in Eli Lilly and were worth $703,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Beutel Goodman & Co Ltd. purchased a new stake in shares of Eli Lilly and during the first quarter valued at approximately $161,084,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. Winslow Capital Management LLC increased its stake in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares during the last quarter. 75.61% of the stock is owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Company (LLY) traded down 0.74% on Thursday, reaching $81.96. 307,448 shares of the company traded hands. The firm has a 50-day moving average price of $83.02 and a 200 day moving average price of $81.68. The company has a market capitalization of $86.47 billion, a PE ratio of 35.47 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the business posted $0.86 EPS. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY NOTICE: “DF Dent & Co. Inc. Maintains Position in Eli Lilly and Company (LLY)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/df-dent-co-inc-maintains-position-in-eli-lilly-and-company-lly/1470695.html.

LLY has been the subject of several recent analyst reports. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $92.00 target price on shares of Eli Lilly and in a research note on Tuesday, May 16th. BMO Capital Markets set a $71.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, April 25th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $87.00 target price on shares of Eli Lilly and in a research note on Wednesday, April 19th. Finally, Argus downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating and upped their target price for the company from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $88.27.

In other news, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. In the last quarter, insiders sold 669,733 shares of company stock valued at $55,845,287. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.